Market Size of Latin America Alpha-Glucosidase Inhibitors Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 3.30 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Latin America Alpha-Glucosidase Inhibitors Market Analysis
The Latin America Alpha-Glucosidase Inhibitors Market size is expected to grow from USD 72.47 million in current year to USD 85.24 million by forecast year, at a CAGR of 3.30% during the forecast period.
The COVID-19 pandemic has been testing the capacity to respond and adapt to populations, governments, and health systems worldwide. In the Latin America region, Brazil presented the first suspected and the first confirmed cases on January 27th and February 26th, respectively. Most Latin American countries failed to implement timely measures to protect individuals with diabetes, which may severely impact individuals, health systems, and economies.
The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.
This is driving the demand for Alpha-Glucosidase Inhibitors in Latin America, thereby driving the market in focus during the forecast period.
Latin America Alpha-Glucosidase Inhibitors Industry Segmentation
Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. They block enzymes that convert complicated non-absorbable carbs into simple absorbable carbohydrates by competitive inhibition. The Latin America Alpha-Glucosidase Inhibitors Market is segmented by by Drug (Alpha-Glucosidase Inhibitors) and Geography (Brazil, Mexico, and the Rest of Latin America). The report offers the value (in USD) and Volume (in Unit) for the above segments.
| Drug | |
| Alpha-glucosidase Inhibitors |
| Geography | |
| Brazil | |
| Mexico | |
| Rest of Latin America |
Latin America Alpha-Glucosidase Inhibitors Market Size Summary
The Latin America Alpha-Glucosidase Inhibitors Market is poised for growth, driven by the high prevalence of Type-2 diabetes in the region, particularly in countries like Mexico and Brazil. The increasing rates of obesity and genetic predisposition have contributed to a significant rise in diabetic patients, with Type-2 diabetes accounting for the majority of cases. The demand for Alpha-Glucosidase Inhibitors is expected to rise as these medications play a crucial role in managing blood sugar levels and improving metabolic profiles without causing serious side effects. The market's expansion is further supported by the healthcare infrastructure in Brazil, which offers various programs to enhance access to essential medicines and primary healthcare, despite challenges such as late diagnosis and high treatment costs.
The market landscape is characterized by a high degree of fragmentation, with key players like Bayer, SunPharma, Pfizer, and Takeda actively participating in the region. These companies are involved in ongoing research and development efforts, including drug repurposing studies to optimize existing FDA-approved drugs for better efficacy against α-glucosidase. Regulatory actions, such as price fixing by the National Pharmaceutical Pricing Authority, also influence market dynamics. The interdisciplinary approach to managing Type-2 diabetes, involving primary care providers, pharmacists, and nurse practitioners, is essential for patient education and dietary management, further supporting the market's growth trajectory during the forecast period.
Latin America Alpha-Glucosidase Inhibitors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Drivers
-
1.3 Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. Market Segmentation
-
2.1 Drug
-
2.1.1 Alpha-glucosidase Inhibitors
-
-
2.2 Geography
-
2.2.1 Brazil
-
2.2.2 Mexico
-
2.2.3 Rest of Latin America
-
-
Latin America Alpha-Glucosidase Inhibitors Market Size FAQs
What is the current Latin America Alpha-Glucosidase Inhibitors Market size?
The Latin America Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 3.30% during the forecast period (2024-2029)
Who are the key players in Latin America Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, Sun Pharma and Glenmark are the major companies operating in the Latin America Alpha-Glucosidase Inhibitors Market.
